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Abstract
Background: Recent reports suggest that latrepirdine (Dimebon™, dimebolin), a retired Russian
antihistamine, improves cognitive function in aged rodents and in patients with mild to moderate
Alzheimer's disease (AD). However, the mechanism(s) underlying this benefit remain elusive. AD
is characterized by extracellular accumulation of the amyloid-β (Aβ) peptide in the brain, and Aβ-
lowering drugs are currently among the most popular anti-amyloid agents under development for
the treatment of AD. In the current study, we assessed the effect of acute dosing of latrepirdine
on levels of extracellular Aβ using in vitro and in vivo experimental systems.
Results: We evaluated extracellular levels of Aβ in three experimental systems, under basal
conditions and after treatment with latrepirdine. Mouse N2a neuroblastoma cells overexpressing
Swedish APP were incubated for 6 hr in the presence of either vehicle or vehicle + latrepirdine
(500pM-5 μM). Synaptoneurosomes were isolated from TgCRND8 mutant APP-overexpressing
transgenic mice and incubated for 0 to 10 min in the absence or presence of latrepirdine (1 μM or
10 μM). Drug-naïve Tg2576 Swedish mutant APP overexpressing transgenic mice received a single
intraperitoneal injection of either vehicle or vehicle + latrepirdine (3.5 mg/kg). Picomolar to
nanomolar concentrations of acutely administered latrepirdine increased the extracellular
concentration of Aβ in the conditioned media from Swedish mutant APP-overexpressing N2a cells
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by up to 64% (p = 0.01), while a clinically relevant acute dose of latrepirdine administered i.p. led
to an increase in the interstitial fluid of freely moving APP transgenic mice by up to 40% (p = 0.01).
Reconstitution of membrane protein trafficking and processing is frequently inefficient, and,
consistent with this interpretation, latrepirdine treatment of isolated TgCRND8
synaptoneurosomes involved higher concentrations of drug (1-10 μM) and led to more modest
increases in extracellular Aβx-42 levels (+10%; p = 0.001); of note, however, was the observation
that extracellular Aβx-40 levels did not change.
Conclusions: Here, we report the surprising association of acute latrepirdine dosing with elevated
levels of extracellular Aβ as measured in three independent neuron-related or neuron-derived
systems, including the hippocampus of freely moving Tg2576 mice. Given the reported association
of chronic latrepirdine treatment with improvement in cognitive function, the effects of chronic
latrepirdine treatment on extracellular Aβ levels must now be determined.
Background
Alzheimer disease (AD), the major cause of late-life
dementia, is neuropathologically distinguished by the
accumulation in brain of extracellular protein deposits of
the amyloid-β (Aβ) peptide. A large body of evidence sug-
gests that the major underpinnings of the cognitive
decline associated with AD are synaptic and neuronal loss
and tauopathy that occur in association with aggregation
of Aβ peptide to form a range of structures including high-
molecular weight soluble oligomers [1-6]. Most studies
have focused on extracellular accumulation of Aβ,
although aggregation of the peptide inside intracellular
[7-9] transport vesicles has also been described. Current
formulation of the "amyloid hypothesis of AD" is that
aggregated forms of Aβ, which build up in the human
brain over 10-20 years while individuals are still cogni-
tively intact, lead to slowly progressive neurodegeneration
and dementia [10]. Hence, drug discovery programs
aimed at lowering extracellular Aβ levels have become
mainstream in many academic and pharmaceutical AD
therapeutics units [5]. Recently, in a double-blind, pla-
cebo-controlled clinical trial, the retired Russian antihista-
mine latrepirdine (Dimebon™, dimebolin) improved and
stabilized cognitive function of patients with mild to
moderate AD over a one year period [11]. In addition,
latrepirdine demonstrated a small benefit in cognitive
function in Huntington's disease (HD) [12].
In laboratory studies, latrepirdine has also been associ-
ated with an improvement in learning behavior in the rat
AF64A model of acetylcholine deficiency [13,14]. A screen
against a panel of biochemical targets in vitro indicated
that latrepirdine demonstrates a number of bioactivities,
including modulation of Ca2+ flux [15] and apoptosis, as
well as >90% inhibition of α-adrenergic receptors (α1A,α1B, α1D, α2A), histamine receptors (H1 and H2), and sero-
tonin receptors (5-HT2C, 5-HT5A, 5-HT6) at 10 μM concen-
tration [16]. Latrepirdine also potentiates the activity of
AMPA receptors in rat cortical and cerebral Purkinje neu-
rons at low concentrations and blocks NMDA receptor-
induced currents at higher concentrations [17]. A role in
mitochondrial stabilization has also been suggested [18].
However, it is not yet known whether the observed clini-
cal benefits to AD or HD patients are related to any of
these effects or to as-yet undiscovered mechanism(s).
Neurotransmitters [19-22], hormones [19,20,23,24], and
mitochondrial actions are also associated with changes in
Aβ metabolism [20]. Based on this knowledge and on the
drug's possible clinical benefit, we investigated whether
latrepirdine regulates Aβ levels in in vitro and in vivo exper-
imental systems. We observed that acute administration
of clinically relevant levels of latrepirdine stimulated
extracellular accumulation of Aβ in three extracellular sys-
tems, namely: (1) the conditioned media of cultured
human Swedish mutant (Swe)APP-transfected mouse
neuroblastoma cells, (2) the releasate of cortical synap-
toneurosomes isolated from TgCRND8 (Swe/Indiana
APP) transgenic mice, and (3) the interstitial fluid from
the brains of freely moving Tg2576 SweAPP transgenic
mice.
Results
Latrepirdine increases extracellular Aβ levels in 
conditioned media of cultured cells
To examine the effects of latrepirdine on Aβ generation in
vitro, we treated neuroblastoma (N2a) cells stably overex-
pressing Swedish APP [25] for 6 hours either in the
absence (vehicle) or presence of latrepirdine (ranging
from 500 pM to 5 μM, as indicated). Latrepirdine was cus-
tom synthesized by two independent sources. Both com-
pounds were used for each experiment (Figure 1), and no
differences were observed between the two compounds.
Cells treated with latrepirdine showed an ~30-64%
increase in total extracellular Aβ, as determined by west-
ern blot analysis (Figures 2a, b). The effect of latrepirdine
on extracellular levels of Aβ appeared to be concentration-
dependent, where the lowest concentration (500 pM)
produced no significant increase, 5 nM produced an
approximately half-maximal ~37% increase and 500 nM
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produced a maximal significant ~64% increase in extracel-
lular Aβ as compared to vehicle-treated cells (Figure 2, p =
0.02 and p = 0.01, respectively). The highest concentration
(5 μM) also caused a significant ~59% increase in extracel-
lular Aβ levels (Figure 2; p = 0.02). These data appear to
represent a concentration-dependent effect of latrepirdine
with a maximal significant response at 500 nM (see Figure
2).
The amyloid precursor protein (APP) is processed by
divergent proteolytic pathways. In the predominant path-
way, APP is first cleaved by the α-secretase in the middle
of the Aβ domain, generating a large secreted N-terminal
ectodomain (sAPPα) and an 83 amino acid membrane-
bound C-terminal fragment (CTF; C83-CTF). In another,
amyloidogenic, pathway APP is cleaved first by the β-
secretase, generating a smaller secreted N-terminal ecto-
domain (sAPPβ) and a larger 99 amino acid membrane-
bound C-terminal fragment (C99-CTF). The γ-secretase
complex (PS1, APH-2, PEN-1, Nicastrin) then processes
the CTF to generate either the p3 (from C83-CTF) or Aβ
(from C99-CTF) peptide of varying lengths (i.e. Aβ varies
from 37-44 amino acids in length following γ-secretase
cleavage). A significant increase in secretion of sAPPα was
also observed following 6 h incubation of cultured N2a
cells with 5 nM (~33% increase, p = 0.04) and 500 nM
(~27% increase, p = 0.0006) in comparison to vehicle, but
not with either 500 pM or 5 μM in comparison to vehicle
(Figure 2). The effects of latrepirdine on extracellular Aβ
accumulation may be due to increased overall metabo-
Comparison of latrepirdine 1D NMR proton spectra in DMSO from two sourcesFigure 1
Comparison of latrepirdine 1D NMR proton spectra in DMSO from two sources. Latrepirdine was custom synthe-
sized by either Nanosyn Inc or SinoChemexper and purity was determined to be ~97.3% or >99.0%, respectively. 1D NMR 
proton spectra are compared here for latrepirdine synthesized by SinoChemexper (top) or Nanosyn (bottom, reprinted with 
permission from Wu et al, 2008 [16]). Aliquots of latrepirdine from both sources were tested in each protocol. Identical 
effects were observed regardless of source of compound, and data were pooled for overall analysis.
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Effect of latrepirdine on the levels of APP metabolites from cell lysates and conditioned media of mouse N2a cellsFigure 2
Effect of latrepirdine on the levels of APP metabolites from cell lysates and conditioned media of mouse N2a 
cells. Cells were treated for 6 hours in the presence of vehicle or increasing concentrations of latrepirdine (as labeled). (a) 
Representative western blot of total intracellular and secreted metabolites of APP from at least 3 independent experiments, 
each performed in duplicate. (b) Quantification of western blot band densitometry represented as mean percent of vehicle +/- 
S.E.M. 5 nM latrepirdine produced an approximately half-maximal ~37% increase (SD = 0.33, t(10) = 2.75, p = 0.02), and 500 
nM produced a maximal significant ~64% increase (SD = 0.49, t(10) = 3.16, p = 0.01) in extracellular Aβ compared to vehicle. 
The highest concentration (5 μM) also caused a significant ~59% increase (SD = 0.52, t(10) = 2.78, p = 0.02) in extracellular Aβ 
levels, and an increase in extracellular Aβ levels was observed with 50 nM latrepirdine, which approached significance on a 
two-tailed test (SD = 0.54, t(4) = 2.62, p = 0.059). Incubation with 5 nM or 500 nM latrepirdine resulted in a significant ~34% 
(SD = 0.35, t(10) = 2.33, p = 0.04) and ~27% (SD = 0.14, t(10) = 4.87, p = 0.0006) increase in sAPPα accumulation, respectively, 
in conditioned media compared to vehicle. An increase in extracellular sAPPα levels was observed with 50 nM latrepirdine, 
which approached significance on a two-tailed test (SD = 0.53, t(4) = 2.31, p = 0.081). No significant increases in sAPPα levels 
were distinguished between vehicle and either 500 pM or 5 μM latrepirdine. No significant accumulation of holoAPP of APP-
CTFs (C83-CTF or C99-CTF) was observed following 6 h incubation in the absence (vehicle) or presence of varying concen-
trations of latrepirdine (as indicated). (c) Vehicle and all latrepirdine concentrations were indistinguishable by mean Aβx-42/Aβx-
40 ratio, quantified by Aβ species-specific sandwich ELISA (mean Aβx-42/Aβx-40, n = 3 independent experiments, each performed 
in duplicate). Absolute Aβx-40 and Aβx-42 levels in the media were ~380-490 pM and ~14-20 pM, respectively. *Value represents 
a significant mean difference from vehicle by independent samples t-test, two-tailed α = 0.05, #p < 0.10; *p < 0.05; **p < 0.01.
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lism of APP, indicative of stimulation of APP trafficking to
the plasma membrane. Therefore, we further investigated
whether latrepirdine affects processing of holoAPP or its
membrane bound CTFs, however no significant differ-
ences in holoAPP, C83, or C99 levels were observed in
comparison to vehicle (Figure 2a). A small and not signif-
icant, but clear increase in accumulation of APP-CTFs and
holoAPP was associated with increased extracellular accu-
mulation of sAPPα and Aβ following incubation with 5
nM or 50 nM latrepirdine, suggesting overall increases in
APP synthesis and metabolism.
Aβx-42/Aβx-40 ratio has been reported to determine propen-
sity for amyloid deposition, perhaps because Aβx-40 antag-
onizes the tendency of Aβx-42 to aggregate [26]. Therefore,
conditioned media from the same experiments were also
analyzed for Aβx-42/Aβx-40 ratio by sandwich ELISA. No sig-
nificant differences in Aβx-42/Aβx-40 ratio were observed
between vehicle and any concentration of latrepirdine
tested (Aβx-42/Aβx-40 was ~1:25 for all conditions, Figure
2c). Accumulation of APP-CTFs is often associated with
inhibition of the γ-secretase complex cleavage of their
membrane-bound substrates and changes in Aβx-42/Aβx-40
ratio is also often indicative of altered γ-secretase activity.
Here, we observed neither accumulation of APP-CTFs nor
altered Aβx-42/Aβx-40 ratio, strongly suggesting that
latrepirdine does not regulate γ-secretase activity in N2a
cells.
Latrepirdine stimulates acute secretion of Aβx-42 from 
isolated cortical synaptoneurosomes
TgCRND8 mice encode a double mutant form of human
APP, harboring both Swedish and Indiana mutations
under the control of the PrP gene promoter, resulting in a
significantly increased Aβx-42/Aβx-40 ratio [27]. A recent
report indicated that synaptic activity reduces intraneuro-
nal Aβ by promoting APP transport to synapses and secre-
tion of Aβ into extracellular space, protecting against Aβ-
related synaptic alterations [28]. Based on a brief size-
selection of synaptic particles, isolated cortical synapton-
eurosome preparations from P10-P14 TgCRND8 mice
provide an intact, synapse-specific [29] method for the
study of nerve terminal biology that we have applied to
the study of signal-mediated generation and secretion of
Aβ. The releasates from synaptoneurosomes were col-
lected at 0 (baseline), 1, 3, 5, and 10 minutes following
incubation with either 1 μM or 10 μM latrepirdine and
analyzed for Aβx-42 and Aβx-40 levels by sandwich ELISA. A
paired samples t-test was used to compare mean Aβx-42 or
Aβx-40 levels for each post-treatment time point versus
baseline for each concentration of latrepirdine. Treatment
of synaptoneurosomes with 1 μM (Figure 3a) or 10 μM
(Figure 3b) latrepirdine resulted in increased secretion of
Aβx-42, but not Aβx-40. A 10% increase of secreted Aβx-42,
but not Aβx-40, was observed at 1 minute following incu-
bation with 10 μM latrepirdine (p = 0.001). Similar
increases were observed at 3 minutes and 5 minutes fol-
lowing stimulation (8% increase at 3 minutes, p = 0.0007;
7.6% increase at 5 minutes, p = 0.0029, respectively).
Latrepirdine at 1 μM stimulated a significant 7% increase
in secretion of Aβx-42, but not Aβx-40, following 3 minutes
of incubation (p = 0.048). Releasates were also analyzed
for Aβx-42/Aβx-40 ratio (Figure 3c) and a significant increase
in Aβx-42/Aβx-40 ratio was observed in only one condition:
i.e., Aβx-42/Aβx-40 ratio increased by ~4.1% following 1
minute incubation with 10 μM latrepirdine (p = 0.024).
Acute (single dose) of latrepirdine increases ISF Aβx-40 
levels in the hippocampus of freely moving mice
Brain ISF soluble Aβx-40 levels in the hippocampus of
freely moving Tg2576 mice expressing human Swedish
APP were measured by in vivo microdialysis using a 38
kDa molecular weight cut-off probe membrane, as previ-
ously described [30-32]. ISF samples were collected every
60 minutes for 6 hours prior (baseline) to intraperitoneal
(i.p.) injection of either 0.9% saline (vehicle, n = 5) or 3.5
mg/kg latrepirdine (n = 5), and for 10 hours following
injection (post-treatment period) and analyzed for Aβx-40
content by sandwich ELISA, as previously described [30-
33]. This dose of latrepirdine is comparable to that of a
single dose used in the clinical trial of AD patients [11]
after normalization to the body surface area of mice. Base-
line ISF Aβx-40 levels were averaged for each mouse and an
independent samples t-test confirmed that there was no
significant difference in baseline ISF Aβx-40 levels for vehi-
cle versus control mice (data not shown). Each time point
was normalized to reflect percent baseline for each
mouse, and paired samples t-tests reflected significant
41% increase in Aβx-40 levels following treatment with
latrepirdine (p = 0.04), but not for vehicle (~5% decrease;
p = 0.48). The elevation lasted for a mean of 9-10 hours
post-treatment (Figure 4a). An independent samples t-test
of mean latrepirdine versus vehicle ISF Aβx-40 levels from
9-10 hours post-treatment confirmed a significant
increase in ISF Aβx-40 levels for latrepirdine compared to
vehicle (41% increase versus 5% decrease, respectively; p
= 0.01, Figure 4b).
Conclusions
In this report, we show in three systems that latrepirdine
significantly increases extracellular Aβ levels ranging from
5-65% depending on the system and time course of study.
While the mechanism of this effect is not entirely clear,
latrepirdine has been reported to modulate a variety of
neurotransmitter systems [12-17]. Given the apparent
benefit of latrepirdine in two neurodegenerative diseases
of disparate pathogenesis (i.e., AD and HD), latrepirdine-
induced changes in neurotransmission, coupled with
altered synaptic activity, may account for the rapid
changes in Aβ levels we observed. Whether these rapid
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Secreted Aβx-40 and Aβx-42 levels in the releasates of synaptoneurosomes following incubation with latrepirdineFigur  3
Secreted Aβx-40 and Aβx-42 levels in the releasates of synaptoneurosomes following incubation with latrepirdine. 
Post-natal day 10-14 TgCRND8 cortical synaptoneurosomes were incubated 0 (baseline), 1, 3, 5, or 10 minutes in the pres-
ence of 1 μM (n = 5) or 10 μM (n = 6) latrepirdine. (a) 1 μM latrepirdine stimulates an increase in secretion of Aβx-42, but not 
Aβx-40, from isolated synaptoneurosomes following 3 minutes (SD = 0.06, t(4) = 2.81, p = 0.048) of incubation with the drug, 
and a decrease (~6%) is observed at 10 minutes (SD = 0.01, t(5) = 9.61, p = 0.0007), likely representing a depletion of available 
Aβx-42 (mean % baseline +/- S.E.M). (b) 10 μM latrepirdine stimulates an increase in secretion of Aβx-42, but not Aβx-40, following 
1 (SD = 0.038, t(5) = 6.73, p = 0.001), 3 (SD = 0.028, t(5) = 7.35, p = 0.0007), and 5 (SD = 0.056, t(5) = 5.29, p = 0.0029) min-
utes of incubation with the drug (mean % baseline +/- S.E.M). (c) An immediate ~4.1% increase (SD = 0.13, t(5) = 3.205, p = 
0.024) in Aβx-42/Aβx-40 ratio was observed following 1 minute of incubation with 10 μM latrepirdine (mean Aβx-42/Aβx-40). 
(Note: TgCRND8 mice generate ~50%/50% Aβx-42/Aβx-40 under normal conditions and the increase in Aβx-42/Aβx-40 ratio may 
be due to the large stimulation of Aβ secretion at this time point). *Value represents a significant mean difference between 
baseline and time-point by paired t-test, two-tailed α = 0.05, *p < 0.05, **p < 0.01.
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latrepirdine-induced changes in soluble Aβ levels feed
back to influence synaptic function was not assessed in
these studies, nor did we study the long-term effects on Aβ
metabolism of latrepirdine over days to months. Thus, it
is unknown whether latrepirdine would effect Aβ accumu-
lation in the brain over longer periods of time.
Examples of rapid increases in Aβ release via different
mechanisms have been described, e.g. insulin application
to cultured neurons stimulates Aβ secretion [23]. There-
fore, one speculation is that insulin and sensitizers, which
have been shown to be clinically beneficial for treatment
of AD [34], might alter growth factor signaling to influ-
ence APP processing or synaptic activity [28] to result in
Aβ release. Here, we report stimulation of Aβ secretion by
Acute administration of latrepirdine increases ISF Aβx-40 levels 9-10 hours following treatmentFigure 4
Acute administration of latrepirdine increases ISF Aβx-40 levels 9-10 hours following treatment. A single i.p. treat-
ment of latrepirdine (SD = 30.94, t(4) = 2.997, p = 0.04), but not vehicle (SD = 5.68, t(4) = 0.775, p = 0.48), produces an 
increase in ISF Aβx-40 levels from baseline at 9-10 hours post-treatment (a). This increase in ISF Aβx-40 level was also deter-
mined to be significantly higher than ISF Aβx-40 levels observed in vehicle treated animals at 9-10 hours post-treatment (SD = 
30.94, t(5) = 3.31, p = 0.01; b). Data are represented as mean percent of baseline +/- S.E.M. *Value represents a significant dif-
ference as determined by paired samples t-test (a) or independent samples t-test (b), two-tailed α = 0.05, *p < 0.05.
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yet another clinically beneficial drug (latrepirdine),
through a yet unknown mechanism, which may be regu-
lated by synaptic activity (Figures 3a and 3b).
Recent evidence demonstrates that synaptic activity can
dynamically alter ISF Aβ levels in vivo [30]. Further sup-
port for regulation of APP metabolism and Aβ secretion
by synaptic activity was recently published, indicating that
synaptic activity protects against Aβ-related synaptic alter-
ations by promoting transport of APP to synapses and
secretion of Aβ at the synapse, reducing intraneuronal Aβ
[28]. Aβ was also recently shown to act as a positive
endogenous regulator of release probability at hippocam-
pal synapses [35]. It is also worth noting that Aβ dynami-
cally fluctuates in the ISF of humans recovering from
brain injury [33]. In these situations, clinical trends
toward recovery of normal, conscious cerebral activity are
consistently associated with elevations of ISF Aβ levels
[33,36]. Consistent with this model are data indicating
that there are diurnal variations in Aβ metabolism, with
Aβ levels peaking during wakefulness and declining dur-
ing sleep [37]. Arancio and colleagues have demonstrated
that these physiological picomolar concentrations of Aβ
are actually essential for long-term potentiation (LTP) for-
mation, and only with nanomolar concentrations does Aβ
interfere with LTP [38].
A recent report indicates that latrepirdine inhibits aggrega-
tion of TDP-43 (~40% inhibition at 5 μM) in a cellular
model of TDP-43 proteinopathy [39], suggesting that
latrepirdine may also offer anti-oligomerization proper-
ties. High-molecular weight soluble oligomeric (HMW
s.o.)Aβ species have been previously shown to produce
AD-like cognitive deficits in vivo [2], and clearance of
HMW s.o.Aβ ameliorated these deficits [2-4]. The
reported benefits in AD and HD associated with latrepird-
ine treatment may be related to anti-oligomerization
properties, though this question was not investigated
here. Further investigation is necessary to determine
whether latrepirdine disrupts the formation of HMW
s.o.Aβ species.
In regard to the recently published effects of latrepirdine
enhancing cognition in AD [11,13] and HD patients, it is
possible that the observed effects are due to its effects on
neurotransmitter receptors in the CNS [16,17]. Likewise,
the effects we are observing on Aβ metabolism may also
be related to effects on neurotransmitter receptors. The
relationship between latrepirdine and the typical neuro-
transmitter replacement therapy associated with AD (i.e.
cholinesterase inhibition) is also unknown, although the
side effect profile of latrepirdine [11] is not consistent
with cholinergic stimulation [40]. Whether the effects of
latrepirdine on cognition and Aβ levels are directly related
or are coincident is unknown. Further studies are required
to determine the long-term effects of latrepirdine on Aβ
and the mechanistic link, if any, with the observed human
cognitive benefit.
Methods
Preparation and handling of latrepirdine
Latrepirdine was synthesized and characterized by SinoC-
hemexper (Shanghai, China) or Nanosyn Inc (Menlo
Park, CA; characterization previously [16]) and no signif-
icant differences in effects were observed between the two
compounds (data not shown). 1D proton NMR spectra of
both compounds are shown in Figure 1. Latrepirdine syn-
thesized by Nanosyn Inc and SinoChemexper were deter-
mined to be 97.3% and >99.0% pure, respectively.
Latrepirdine was freshly dissolved into serum/antibiotic-
free high glucose DMEM (DMEM; Gibco) to 1 mM stock
and diluted to experimental concentrations in DMEM for
cell culture experiments. For synaptoneurosome experi-
ments, latrepirdine was dissolved into dimethylsulfoxide
to 10 mM stock and diluted to experimental concentra-
tions in ion-balanced homogenizing buffer [50 mM
Hepes, pH 7.5, 125 mM NaCl, 100 mM sucrose, 2 mM
potassium acetate and protease inhibitor cocktail
(Pierce)]. For in vivo experiments, latrepirdine was dis-
solved into 0.9% saline (vehicle) at a final concentration
of 3.5 mg/ml (prepared fresh every 2 days).
Cell culture experiments
Mouse N2a neuroblastoma cells stably overexpressing
human Swedish (K670N, M671L) APP [25] were the gen-
erous gift of Dr. Gopal Thinakaran (University of Chi-
cago). Cell were cultured to ~80% confluency in growth
media [DMEM, 10% FBS (Gibco), 1% Pen-Strep (Gibco),
0.2 mg/ml G418 (Sigma)] prior to treatment with drug.
Cells were washed 1× with ice cold PBS (pH 7.4) then
incubated with either latrepirdine or vehicle (DMEM).
Conditioned media was collected following 6 hours of
treatment, cells were washed 1× with ice cold PBS, and
cells were lysed and collected in 1× lysis buffer [20 mM
Tris, 137 mM NaCl, 1 mM EDTA, 1 mM pepstatin, 1 mM
PMSF, 5 mM ZnCl2, 1% Triton X-100, EDTA-free mini-
complete protease inhibitor cocktail tablet (Roche)] then
centrifuged (14,000 RPM) for 15 minutes at 4°C. Follow-
ing BCA protein estimation assay (Pierce), 30 μg total pro-
tein from conditioned media or 15 μg total protein from
cell lysates was loaded onto a 12% Bis-Tris (Bio Rad) gel
for SDS-PAGE with NuPage MES buffer (Invitrogen) at
200 V for 35 minutes, then transferred to PVDF mem-
brane (0.22 μm for conditioned media or 0.45 μm for cell
lysates; Millipore) using the Trans-Blot SD transfer appa-
ratus (Bio-Rad). Following transfer, the membrane was
boiled for 5 minutes in 1× PBS, blocked for 1 hour in 5%
non-fat milk (Santa Cruz Biotechnology), and incubated
with either mouse mAb 6E10 (Covance, Aβ1-16), rabbit
pAb G369 (APP C-terminus), or mouse mAb anti-Actin
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(Sigma) overnight at 4°C. Membranes were washed 4×,
incubated in HRP-conjugated goat anti-mouse or anti-
rabbit IgG secondary antibody (Vector Laboratories),
washed 4×, and developed with ECL western blotting sub-
strate (Pierce) using the Fujifilm LAS-3000 developer.
Band intensity was measured with MultiGauge (Fujifilm)
software and normalized to percent of vehicle. For
holoAPP and APP CTFs, band density was normalized
first to Actin band density (to control for any loading
error), prior to comparison to vehicle. Total Aβ and sAPPα
levels were compared from conditioned media by western
blot analysis. Conditioned media was also analyzed for
secreted Aβx-42/Aβx-40 ratio by sandwich ELISA (Wako)
according to manufacturer protocols.
Cortical synaptoneurosome preparation from TgCRND8 
mice
Synaptoneurosomes were prepared from the cortices of
postnatal day (P)10-14 TgCRND8 (APP K670N, M671L,
V717F) [27] mice. Briefly, mice were quickly decapitated,
brains were removed and dissected, and cortices were
homogenized in a glass-Teflon homogenizer in homoge-
nization buffer (HB), filtered through a series of nylon
mesh filters (149, 62, and 30 microns; Small Parts) and
then through a 10- μm polypropylene filter (Gelman Sci-
ences) [29]. Filters were washed at each step with HB. The
final filtrate was spun briefly (4,000 × g, 1 min), then the
supernatant was spun (7,000 × g, 15 min) to pellet synap-
toneurosomes. Synaptoneurosomes were resuspended in
the fresh HB. Before drug treatment paradigms, this sus-
pension was incubated on ice while stirring, with 1 μM
tetrodotoxin (Tocris), for 5 min then at room temperature
for another 5 min. Reactions proceeded at room tempera-
ture. Samples were removed and instantly put on ice at 0
(immediately before adding latrepirdine), 1, 3, 5, and 10
minutes following latrepirdine application. Each sample
was spun (20,000 × g, 10 min) and the supernatant was
collected as releasate using protein LoBind tubes (Eppen-
dorf). Samples were analyzed for secreted Aβx-40 and Aβx-
42 by sandwich ELISA (Wako) according to manufacturer
protocols.
In vivo microdialysis of hippocampal interstitial fluid (ISF) 
Aβx-40 levels
Soluble Aβ levels were measured from the brains of 3-
month old Tg2576 hemizygous (Swedish APP) mice as
described previously [30-32]. Briefly, Tg2576 mice
received a single dose of 3.5 mg/kg latrepirdine (n = 5) or
equivalent volume of vehicle (n = 5) by intraperitoneal
(i.p.) injection. In vivo microdialysis was used to assess
hippocampal ISF levels of Aβx-40 from awake, freely mov-
ing Tg2576 mice (as described [32]). Samples were col-
lected (by refrigerated fraction collector) every 60 minutes
for 6 hours prior to injection (baseline) and 10 hours fol-
lowing injection of drug or vehicle. Aβx-40 levels were
assessed by sandwich ELISA following completion of the
experiment (described previously in [30,32]). During
microdialysis, awake and freely moving mice were housed
in constant light with ad libitum access to food and water.
Statistical analysis
For quantification of total holoAPP, APP-CTFs, Aβ and
sAPPα from cell lysates and conditioned media, inde-
pendent samples t-tests were utilized to determine signif-
icant mean differences for each condition versus control.
For synaptoneurosome time-course experiments, paired
samples t-tests were used to determine pre-treatment ver-
sus post-treatment differences of secreted Aβx-40 and Aβx-42
levels, and for Aβx-42/Aβx-40 ratios. For microdialysis time-
course experiments, 6 pre-treatment ISF samples were col-
lected and analyzed for Aβx-40 levels, averaged for each
animal to produce a baseline value of ISF Aβx-40 levels, and
each time point was normalized to percent of baseline for
each animal. Paired samples t-test was used to determine
baseline versus 9-10 hour post-treatment differences for
ISF Aβx-40 levels and independent samples t-tests were uti-
lized to compare mean post-treatment ISF Aβx-40 levels for
vehicle versus latrepirdine. Significance for t-tests are
reported with a p < 0.05 using two-tailed tests with an α-
level of 0.05.
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